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Several lines of experimental evidence have suggested that one or more peptides
that canenhance vascular permeabilitymay be released from the second component
ofhuman complement, C2 (1-5) . This possibility is important to understanding the
molecular mechanisms that lead to bouts of circumscribed edema to which persons
with hereditary angioneurotic edema (HANE)' are susceptible. Persons with this
disorder have defects in thebiosynthesis of Cl inhibitor, which are inherited as au-
tosomal dominant traits and are markedly deficient in serum inhibitory activity
directed against the activated firstcomponent ofcomplement, C1 (6, 7) . An acquired
form of this disease, which occurs as a result of C1 inhibitor depletion, has also been
reported (8-11) .
The mediators of the enhanced vascular permeability that leads to edema forma-
tion when C1 inhibitor is deficient are not known . Cl activity is strictly controlled
by C1 inhibitor (12), which binds covalently to the C1 complex (13-16) . Since Cl
inhibitor is the only identified inhibitor of Clr and Cls, the absence or depletion
of this plasma componentresults in a loss of regulation of the early steps of the clas-
sical complement pathway . It has been shown in patients with HANE that C2 and
C4 levels are low during and after an attack (1) . The present studies are a direct
approach to determining ifC2 fragments, which can be released by C1 and other
plasma proteases inhibited by Cl inhibitor, contribute toenhanced vascular perme-
abilityandsubsequent bouts ofangioedema . We have found that asynthetic peptide
of 25 residues identical in sequence to residues 199-223 of the COOH terminus
of C2b has such a property.
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Materials and Methods
Bradykinin.
￿
Commercially available synthetic bradykinin (Bacham Laboratory, Torrance,
CA) eluted as a single sharp peak upon HPLC analysis using application of a 0.0-70.0%
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J . Exp . MED . C The Rockefeller University Press " 0022-1007/88/11/1685/14 $2.00
￿
16851686
￿
COMPLEMENT COMPONENT C2 PEPTIDE INDUCES ANGIOEDEMA
(vol/vol) acetonitrile gradient in 0.1% (vol/vol) TEN onto a reverse-phase column (Brownlee
C18 ; Rainin Instrument Co., Inc ., Woburn, MA) and was then used without further
purification . As a standard for biological assays, bradykinin at 1 mg/ml was made in 0.1%
acetic acid and the exact concentration was determined by compositional analysis ofthe solution .
Enzymes.
￿
Human Cls, in the enzymatically active form and free of contaminating Clr
and plasmin enzymatic activities, was a gift from Dr. David Bing (Center for Blood Research,
Boston, MA) . The concentration of Cls is given in micrograms as determined using an ex-
tinction coefficient at 280 nm of 0.94 ml/(mg cm) .
Human plasminogen was either a gift from Dr. Eileen Remold-O'Donnell (Center for Blood
Research) or, for some experiments, purified usingapublished procedure (17) involving plasma
adsorption to lysine-Sepharose and subsequent elution of plasminogen with c-aminocaproic
acid (Sigma Chemical Co., St . Louis, MO). Immediately before use the plasminogen was
converted to plasmin by incubation with purified streptokinase as previously described (18) .
The conversion from plasminogen to plasmin was always confirmed by SDS-PAGE (19) under
reducing conditions . In the presence of 3% (vol/vol) a-ME, plasminogen migrated as a single
band of 100,000M r and plasmin migrated as two bands of 70,000 and 35,000 M, .
Human C2. C2 was purifed according to Thielens et al. (20) with certain modifications
and additions . The changes are as follows : fresh frozen plasma (Knickerbocker Biological,
New York, NY) was thawed in the presence of 5 mM benzamidine HCl (Sigma Chemical
Co.) and 10" 4M diisopropylfluorophosphate (DFP) . The partially thawed "slush" of plasma
was then dialyzed against sodium phosphate/EDTA with 5 mM benzamidine and 10-5 M
DFP added . No P-ME was added to the ammonium sulfate solutions, and the precipitate
formed at 75% saturation was centrifuged for 60 min . In preparation for CM-Sepharose
chromatography, the precipitiate was dissolved in 20 mM sodium phosphate, 2 mM EDTA,
pH 7 .0, to which 5mM benzamidine and 10-4 M DFP had been added and then dialyzed
against this buffer . Just before CM-Sepharose chromatography, the pH ofthe dialyzed pool
was acidified topH 6.0 with 1M HCI . A CM-Sepharose column with a resin volume equiva-
lent to three times the C2 pool volume and which had been equilibrated in the sodium phos-
phate/EDTA, pH 6.0, buffer was used . The final yield for this procedure was 35-40%2 .
C2 Digestion and Peptide Isolation .
￿
Purified C2 at 1-2 mg/ml was dialyzed into 50 mM
NH4HCO3 and then the dialyzed protein was digested with Cls (1 :100, wt/wt) and plasmin
(1 :20, wt/wt) for 1 h at 37°C . After incubation, the protein solution was either lyophilized
in preparation for HPLC fractionation or analyzed by SDS-PAGE .
The C2b-derived peptides were isolated by a series of two HPLC steps : chromatography
ofthe digest mixture on an Aquapore reverse-phase C8 column, followed by chromatography
of the peptide fraction on a Brownlee reverse phase C18 column . Both HPLC columns were
purchased from Rainin Instruments . The lyophilized digest mixture was dissolved in 0.1%
TFA (vol/vol) and applied to the C8 column, which was equilibrated in 0.1% TFA, 5% acetoni-
trile . The proteolytic fragments were then eluted using a linear acetonitrile gradient of 5-70
(vol/vol) in 0.1% TFA over 30 min . The fractions containing peptides that eluted early were
then rechromatographed on the C18 column, using the same chromatographic conditions
that were used for the C8 column .
Synthetic Peptides.
￿
Directly after cleavage from the Merrifield resin with HF, the synthetic
peptides were lyophilized 8-10 times from water to remove volatile components . The peptides
were then fractionated on a P2 column (5 ml ; Bio-Rad Laboratories, Richmond, CA),
equilibrated in 0.2 M NH4HCO3, pH 8.2, then lyophilized, lyophilized again from H 2O
(three times), and finally brought up in sterile 0.9% saline for testing . Amino acid analysis
of P2-fractionated synthetic peptides of 19 amino acids or shorter in length were nearly inte-
gral, indicating peptides ofsubstantial purity . When analyzed by reverse-phase HPLC, these
same peptides showed a major peak, which accounted for >90% the sample peptide mass ;
by amino acid analysis, this peak was full-length peptide. The amino acid analyses for the
P2 purified synthetic peptides used in this study are shown in Table 1 .
Results from amino acid analysis on the P2-purified C2b 199-223 peptide did not corre-
2 Virtually all the loss of C2 occurs in the two chromatographic steps ; a typical purification table
that includes the yield of C2 at each step in the procedure has been previously published (35) .Mole of amino acid per mole of peptide .
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TABLE I
Amino Acid Compositions of the Synthetic Peptides of C2b
late exactly with the theoretical amino acid composition and HPLC analysis ofthis peptide
showed several peaks . From amino acid analysis of the peptide-containing HPLC fractions
(data not shown), this sample was found to be25% (wt/wt) full-length peptide . Calculations
of biological activity reflect this ratio.
NHZ-terminal Amino Acid Sequence Analysis.
￿
Automated Edman degradation was performed
using 25% trifluoroacetic acid at 50°C for 27 min with a sequencer updated with
microprocessor control and automated conversion (Beckman Instruments, Inc., Fullerton,
CA) . A 0 .1 M Quadrol program was used . Phenylthiohydantoin derivatives were identified
byHPLC using a ZorbaxPTH column developed isocratically with 6mM phosphoric acid,
pH 3.15, acetonitrile, and tetrahydrofuran, (66:19:15) .
Peptide Synthesis.
￿
Synthetic peptides were made by solid-phase synthetic techniques as de-
veloped by Merrifield and colleagues (21, 22) .
SDS-PAGE.
￿
PAGE under denaturing and reducing conditions was performed as described
(19), with one exception ; to separate C2 and factor B, an acrylamide/bis acrylamide ratio
of 30:0.016 was used .
C2 Functional Activity .
￿
C2 was assayed for functional activity using a hemolytic assay de-
scribed by Rapp and Borsos (23) . Sheep erthrocytes sensitized with anti-Forsmann antibody
and bound Cl (guinea pig) and C4 (human) on the surface were used as a source of early
complement components and rat serum (1 :3 dilution into veronal buffered saline with 10
mM EDTA, pH 7.35, and gelatin [0.1%, wt vol] [GVB-EDTA]) was used as a source ofC3-9 .
TheC2 titer ofthe partially purified C2 was compared with aC2 titer determined for normal
human serum to estimate the concentration of functional C2 . In addition, C2 was found
to be free of plasma kallikrein asjudged by the inability ofC2 fractions to reconstitute Fletcher
factor-deficient plasma (George King Biomedical, Inc ., Overland Park, KS) as described
(24) . The purified C2 was also found to be free of kinin precursors as demonstrated by the
lack of contractile activity on estrous rat uterus after incubation with human urinary kal-
likrein at 37'C for 10 min .
Induction of Rat Uterus Contraction.
￿
The ability of each peptide to induce contraction of
a rat estrous uterus was used to test the biological activity of these peptides (25) . A portion
(1-2 cm) of excised rat uterus was hung in an aerated bath (5 ml) of dejalon's buffer, and
connected to a strain gauge transducer (Adaps, Inc., Dedham, MA) . The uterus was stan-
dardized with a solution ofbradykinin (0.1-1 pmol) in water, the concentration of which was
determined by amino acid analysis . The synthetic C2b peptides in 50mM acetic acid were
then tested . Buffers ofPBS or normal saline were also used for solubilization ofthe peptides .
A standard curve for bradykinin was determined three or four times per day and doses of
bradykinin that induced 20% and 70% maximal contraction were given just before and im-
mediately after a dose of synthetic peptide . The solution concentration for each synthetic
peptide was standardized by compositional analysis . For biological measurements oftheC2b
fragments that had been generated by Cls and plasmin, fractions were collected in plastic
tubes, lyophilized, and dissolved in 50mM acetic acid (200 pl), and assayed as described .
Skin VascularPermeability.
￿
Adult guinea pigs (500-800 g) were assayed for skin vasoperme-
Amino acid compositions"
Peptide Asp Thr Glu Pro Lys Ser Leu Gly Arg Ala Met Phe His
C2b 212-216 0 .88 1 .02 1.08 0.98 1 .03
C26 219-223 0 .96 0.85 0.94 1 .10 1 .15
C2b 217-223 0.86 0.97 0.87 0.95 0.97 1 .16 1 .22
C2b 214-223 1 .92 2 .27 2.04 0.74 1 .08 0.84 1 .10
C2b 207-223 1 .05 3 .11 2 .33 1 .29 2 .15 0.79 1 .85 1 .71 1 .11 0.95 0.66
C2b 199-223 1 .71 3 .54 3 .59 1 .81 2 .00 3.11 1 .96 10.12 1 .45 2.06 0.43 0.44 0.911688
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ability by Evans Blue extravasation . Evans Blue (0.17o in 0.15M NaCl, 0.2 ml/100 g body
weight) was injected intravenously into the foreleg . The abdominal area of the guinea pig
was then shaved and the peptides in 0 .1 ml PBS were injected intradermally . The extent of
vascular permeability enhancement was assessed as described previously (5) .
To quantify the enhancement ofhuman skin vascular permeability, the peptides in 0 .1 ml
sterile saline were injected intradermally into the forearm of normal individuals . For each
dose, the diameter was measured at 5-8 min after injection. Wheal area was calculated as
ttr2 , where r = (d, + d2)/4 . The wheal area was corrected for any buffer contribution by
subtracting the lesion area of control injections. From a plot of area vs . log peptide dose,
the peptide dose at half-maximal area was determined .
EM
￿
At 5 min after injection of the C2b 199-223 peptide, a punch biopsy was taken .
The skin fragment was immediately fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer,
pH 7.3, for 3 h at room temperature . The tissue was then washed overnight in 0.15M caco-
dylate buffer, pH 7.3 . The tissue was then post-fixed in 1.3% Os04 in s-Collodine, pH 7.2 .
Staining was carried out en bloc in 1.5% uranyl acetate in 0.05 M maleate buffer, pH 6.2 .
After dehydration in graded ethanol, the tissue was embedded in Epon. Thin sections were
cut on an LKB ultratome IV, (LKB Instruments, Inc ., Gaithersburg, MD), picked up on
carbon-coated grids, lightly stained with lead citrate, and examined in an electron micro-
scope (model 300 ; Phillips Electronic Instruments, Inc., Mahwah, NJ) .
Results
C2 Purification and Digestion with Cls and Plasmin .
￿
On SDS-PAGE analysis, the
affinity-purified C2 appeared as oneband (Fig . 1, lane 1) with anMr of 93,000 . On
SIDS-PAGE, (19), C2 and factor B comigrated, independent of the percent acryl-
amide polymerization . However, alteration of the acrylamide/(bis-acrylamide) ratio
FIGURE 1 .
￿
SDS-PAGE of C2 and C2 digests . C2 was digested with Cls
(C2/Cls, 500 :1 [wt/wt]), or Cls + plasmin (C2/plasmin, 20 :1 [wt/wt])
at 37°C for 60 min and analyzed by SDS-PAGE. Lane 1, C2 ; lane 2,
C2 + Cls; lane 3, C2 + Cls plasmin .STRANG ET AL.
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from 30:0.8 to 30:0.16 allowed resolution of C2 from factor B. From SDS-PAGE
analysis with the lower bis-acrylamide concentration, it was observed that factor B
copurified with C2 throughout the purification procedure until the last step. At the
last step of purification, factor B was not bound to the C4b column, and was easily
separated from C2.
C2 was completely cleaved by Cls into C2a and C2b, which migrated at 70,000
and 32,000 Mr, respectively (Fig. 1, lane 2). The conversion to C2a and C2b was
catalyzedby Cls at ratios as high as 5,000 (wt/wt) C2 per Cls as previously reported
(20). When C2 was digested with Cls and plasmin, and analyzed by SDS-PAGE,
the relative mobility of C2a was the same as that seen after digestion of Cls alone
whilethe mobility oftheC2b band was faster (Fig. 1, lane 3). The plasmin digestion
product of C2b, C2b', had a relative migration rate corresponding to 28,000 Mr,
amolecular mass of 1.7 kD less than that ofC2b. The addition ofC4 did not change
these results. The pattern on SDS-PAGE of C2 digested with Cls and plasmin was
the same whetherthe digestion buffer was PBS (20 mM KH2PO4), pH 7.4; veronal
buffered saline, pH 7.35, with 5 mM Ca2+ and 0.15 mM Mg2+ ; or 100 mM
NaHC03, pH 8.0; consequently, the proteolytic cleavages of C2 by Cls and plasmin
did not requiredivalent cations. When C2 was incubatedwith plasmin alone, -50%
of the C2 wasconverted to C2aand C2b', and no C2b was present (datanot shown).
The observed conversion of C2b to C2b', therefore, required an enzyme other than
Cls, but required neither cations nor the presence of C4.
Analysis of the C2 Digestion Products.
￿
When C2 that had been digested with Cls
and plasmin was analyzed on a C8 reverse-phase HPLC column, a unique set of
twoto four smallearly peakswas observed. (Fig. 2, A-C). Theseclosely spaced peaks
eluted within a 5% portion of the gradient. When the peptides were analyzed on
the more hydrophobic C18 column, the individual peakseluted again as an unresolved
triplet within a restricted portion of the gradient (10%), suggesting the possibility
that thepeptides were of similar amino acid composition and size. When the HPLC
fractions were assayed for biological activity on an isolated rat uterus, all fractions
containing these peptides induced contraction (Fig. 3).
NH2-terminal sequence analysis of C2b' was performed to determine where the
C2b was cleavedby plasmin. Comparison of the C2b' NH2-terminal sequence with
that of C2 andthe sequence ofC2b derivedfrom cDNA (Fig. 4) revealed substantial
agreement. Notably, thetriplet ofamino acids at sequence positions 6-8 ofG1n,Asn,Va1
in the C2b' sequence occurs at positions 6-8 in the NH2-terminal sequence of C2
and at no other place in the sequence of C2 . The difference in molecular weight
between the two fragments, C2b and C2b, is then due to a loss of mass from the
COOH-terminal portion of C2b.
From the cDNA-derived sequence (26), it can be seen that two lysines and one
arginine, which might serve as potential plasmin cleavage sites, are present in this
region (Fig. 5 A). An incomplete plasmin digest could then result in a mixture of
long peptides of 31, 33, and 38 amino acids in length (C2b 186-216, C2b 186-218,
andC2b 186-223) andshortpeptides oftwo, five, andseven amino acids(C2b 217-118,
C2b 219-223, and C2b 217-223). The short peptides were not seen in the HPLC
profile as the absorbance ofthese peptides is too small to be observed with the mass
of C2 that was used. It is likely that the early eluting triplet of peptides is the C2b
COOH-terminal peptides of 31, 33, and 38 amino acids in length.1690
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FIGURE 2.
￿
Separation of C2 proteolytic fragments on HPLC.
Profiles arefrom HPLC separation ofC2 digests on areverse-phase
C8 column, and are plots of absorbance at 215 nm vs. time. For
digestionandchromatographic conditions, seetext. Pn, plasmin;
Pn.P, plasmin-cleavedpeptides. (A)C2 + Cls + plasmin(C2/en-
zyme as in Fig. 1.). C2, 5 nmol. (B)C2 + Cls. C2, 0.1 nmol. (C)
Cls + plasmin (plasmin/Cls, 5:1). Plasmin, 1 nmol.
FIGURE 3.
￿
Analysis of the C2b peptide fractions from
HPLC by the contraction of estrous rat uterus. Peptide-
containing fractionsfrom HPLC were pooled, lyophilized,
and redissolved in 50 mM acetic acid. Foreach ofthe three
peptide pools, one half of the total sample was tested for
the ability to contract estrous rat uterus. Each sample of
peptide inducedcontraction. The extent of contraction for
each peptide, relative to the other two peptide samples, is
shown as denoted by (+) least, (++) intermediate, and
(+++) most.AA position:
￿
1
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2
￿
3
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C2b seguenae:
￿
ALA PRO -- --- PRLP GLN ASK VAL --- ILE ---
C2 seguenoe, Protein' :
￿
ALA PRD SFR -__ PRO GL1L ASK VAL --- I=
C2 segLiaqe, MA:z
￿
AIA PRO SER CYS PRO GLN ASN VAL ASN IL.E SER
Synthesis andActivity of C2 Peptides.
￿
Peptides were synthesized to test in biological
assays. The putative COON-terminal peptides of31, 33, and 38 aminoacids in length
have common NH2 termini, but distinct COOH termini. Peptides with COOH ter-
mini corresponding to the COON terminus of C2b plasmin cleavage products and
ofincreasing amino acid length were synthesized (Fig. 5B) and tested by intradermal
injections on humanskin. For agivenpeptidedose, the extent of edemasurrounding
theinjection site wasdirectly proportional to thelength ofthe peptide injected (Table
II). The smaller peptides of <10 amino acids required doses of 65 nmol or more
to achieve a half-maximal response, whereas 20 nmol or less of the peptides C2b
207-223 (17 amino acids) and C2b 199-223 (25 aminoacids) were required to achieve
the same response. For the 25-amino acid peptide, a half-maximal response was
observed with 1.5 nmol of peptide.
When synthetic peptides were tested forthe abilityto contract estrous rat uterus,
adifferent correlation of activity to peptide length was found. The penta- and hep-
tapeptides from the COOH terminus of C2b induced the contraction of estrous rat
uterus, whilethe peptide 212-216 had no activity at the concentrations tested (<650
nmol). No substantial differences in activity were observed forpeptides of5-19 amino
acids in length. There was insignificant change in the response induced on the iso-
lated rat uterus by the heptapeptide as compared with the pentapeptide. The pen-
tapeptide, C2b219-223, induced contraction of the rat uterus in amounts of 40-220
nmol and greaterwith ahalf-maximal contraction occuring at 125nmol. Thelonger
FIGURE 5. Possible plasmin
cleavage sites in C2bandthese-
quence of the proposed active
site peptides. (A) Possible plas
ao5
￿
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FIGURE 4. NH2-terminal se-
quence analysis of C2b' and a
comparison ofthis sequence to
published sequences of the
NH2 terminus of C2. (---) No
aminoacid detected at that cycle
in the sequence analysis. (1)
Taken from Kerr and Porter
(34), 1979. (2)Takenfrom Bent-
ley (26), 1986. (3) A small
amount ofCys wasalso present
in this cycle.1692
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TABLE II
Effect of Peptide Length on the Enhancement of
Human Skin Vasopermeability
peptide ofC2b 217-223 induced thecontraction ofthe rat uterus at doses of 100-600
nmol andgreaterwith the half-maximal contractionoccuring at 240 nmol . TheC2b
199-223 peptide of 25 amino acids in length wasmore active ; it induced a like con-
traction ofthe estrous rat uterus at aconcentration 1:20 that ofthe shorterpeptides .
On permeability-enhancing tests with guinea pig skin, a similar dependence on
peptide length as that observed on the rat uterus was found . The small peptides of
five and seven amino acids in length gave half-maximal lesion areas at doses of 340
and 330nmol, respectively, andin both cases the rangeof effective doses was 100-1,000
nmol . Except for the C2b 199-223 peptide of 25 amino acids, the longer peptides
showed no increase in specific activity ; the C2b 199-223 peptide was -100 times
more active than shorter peptides .
Thepermeability-enhancing effects ofpeptideC2b 199-223 onhuman and guinea
pig skin was tested in the presence of antihistamines . Tripelennamine hydrochloride
(150 mg), was administered before human skin testing, and 1.5 h later, serial dilu-
tions ofC2b 199-223 were injected intradermally . At concentrations of peptide re-
quired for a submaximal response, the area of the resultant wheal was not affected
by the drug (Table III). When guinea pigs were administered the antihistaminic
drug, polarimine (1 mg/kg), before testing, the resultantbluing wasless intense and
polarimine appeared toenhancethe vasopermeability inducedby this peptide(Table
IV) .
In electron micrographs of the lesion induced by injection of the peptide C2b
TABLE III
The Effect of Triplennamine Hydrochloride (PBZ) on the Enhancement of
Human Skin Vascular Permeability by CA 199-223
Dose -PBZ
mm?
+ PBZ
mm2
C2b 199-223 :
13 nmol 99 57
6 .5 104 71
3 .8 78 78
1 .9 38 33
1 .0 44 16
Histamine :
1 gg 99 24
Peptides Dose at half-maximal response
nmol
C2b 219-223 >250
C2b 214-223 65
C2b 207-223 17 .5
C2b 199-223 1 .5STRANG ET AL .
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TABLE IV
The Effect of Polarimine on the Enhancement of Guinea Pig Skin
Vasopermeability by C2b 199-223
199-223, evidence ofenhanced vascular permeability was present (Fig. 6) . Gaps at
endothelial cell junctions were present and the endothelial cell nuclei were distorted
so as to suggest that they were contracted.
Discussion
When C2 is digested with Cls and plasmin, small peptides are released from C2b
that induced contraction of estrous rat uterus . Since the NH2-terminal sequence
of plasmin-digested C2b' was identical with the NH2-terminal sequence of C2, it
appears that the plasmin-cleaved peptides were derived from the COOH-terminus
ofC2b (Fig. 7) . Synthetic peptides identical in sequence to the proposed active site
ofC2b were synthesized and shown to induce contraction of estrous rat uterus and
to enhance both human and guinea pig skin vascular permeability . The C2b pep-
tide, C2b 199-223, of25 amino acids in length substantially enhanced vascular per-
meability in human skin at 1 nmol .
The ability of the synthetic peptides to enhancethe vascular permeability of both
human and guinea pig skin was found to proceed in the presence of antihistiminic
drugs, which distinguishes them from the complement anaphylatoxins, Ma, C4a,
and C5a (27-31) .
When isolated C2 wasdigested, the cleavage of the peptides from C2b by plasmin
did not require divalent cations or C4 . Whether or not C4 enhances the kinetics
of cleavage was not determined in the 60-min incubations used in this study.
Avasoactive fragment analogous to the peptide from C2b is not present in factor
B, thus confining this particular vasoactivity to the classical complement pathway.
Factor B, which functions in the alternativepathway C3 convertase in amatter anal-
ogous to the function ofC2 in the classical pathway C3 convertase, has been shown
to have 40% amino acid sequence homology with C2, as well as a similar domain
structure (26) . Activation of factor B with C3b and factor D yields two fragments
that display relative mobilities on SDS-PAGE of 68,000M r (Bb) and 28,000M r (Ba) .
Addition ofplasmin, however, does notchange themobilities of either fragment (data
not shown) .
Dose - Polarimine
mm2
+ Polarimine
mm2
C2b 199-223 :
125 nmol 75 83
62 31 115
31 31 115
15.6 25 47
7 .8 19 35
3 .9 25 21
2 .0 - -
Histamine :
6 wg 323 161694
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FIGURE 6 .
￿
Electron micrograph ofa skin lesion dermal micro vessel after injection ofC2b 207-223 .
Dermal micro vessel (x 10,000) with an RBC in its lumen . Gaps between the two endothelial
cells (arrow heads) are observed. The irregular contour ofthe endothelial cell nucleus (N) suggests
that endothelial cell contraction has occurred .
When C2b synthetic peptides were tested in the guinea pig skin and rat uterus
assays, only a peptide of 25 amino acids in length was more active than peptides
of 5-19 amino acids in length . This contrasts with the effects of the peptides of in-
creasing length onhuman skin in which a steady increase in activity with increasing
C2
FIGURE 7 .
￿
C2 and its fragments that
C2b
￿
C2a
￿
are digestion products of serine pro
-~
￿
teinase cleavage .
Cta
plasminSTRANG ET AI,.
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peptide length was observed . The difference may be due to key differences between
the C2 sequences of rat, guinea pig, and human in this region . As C2 sequence
ofthis region from these animals is not available, we can not make a direct compar-
ison . The synthetic C2 peptides have been shownto have multiple activities .A sum-
mary of the dose responses for the peptides of varying amino acid length is shown
in Table V .
With the exception of the COOH-terminal arginine residue, the sequence of the
putative plasmin-derived 38-amino acid active peptide ofC2b demonstrates no se-
quence homology to bradykinin . There is alsono sequencehomology with C4a and
Ma, and only minimal sequence homology with C5a . The three amino acids of
the COOH terminus of C5a and C2b, Leu,GlyArg, are identical . Both peptides
require these COOH-terminal residues for activity.
The plasmin-derived peptide from C2b that we describe here shares many fea-
tures with that of the previously described peptide kinin-permeability factor iso-
lated from HANE plasma (2) . In the 38-amino acid residues are multiple sites for
either chymotryptic (three sites atC2b residues 189, 191, and 205)andtrypticcleavage
(two sites at C2bresidues 216 and218) . The activity of theHANE peptide was found
to be sensitive to both these serine esterases . This contrasts with the susceptibility
of bradykinin only to chymotrypsin . At pH 8.6, the 38-residue peptide would have
a net charge of zero in contrast to bradykinin which carries a net charge of +2.
Thus, bradykinin would be more electropositive on electrophoresis than this pep-
tide, correlating another reported difference between bradykinin and the peptide
from HANE plasma.
The results of the human skin test coupled with the above correlatives suggest
that aC2b vasoactive fragment may likely play a role in the pathogenesis ofedema
associated withC1 inhibitor deficiency. In HANE, assay ofplasma complement com-
ponents during and after attack revealed normal levels ofC3-9 (1, 32), suggesting
that theswelling episodes arenot mediated by C3aorC5a. Furthermore, symptoms
can not be alleviated by antihistaminic drugs, again suggesting thelack ofMa and
Ma involvement . Thedose of a synthetic C2b peptideof 25 amino acids that causes
substantial edema is equivalent to the amount of precursor C2 in N8 ml of collected
blood, which represents -0.2% the total blood volume in a single individual . These
results are then in keeping qualitatively with previous experiments in which C2-
deficient guinea pigs were supplemented with functionally pure C2, and a C2-
dependent vasopermeability response was observed with as little added C2 as 10%
TABLE V
Relative Biological Activities of C2 Peptides
Peptide
Rat uterus
contraction
uM
Assay
Guinea pig
vasopermeability
pmol
Human skin
vasopermeability
umol
C2b 219-223 or 217-223 10 0.5 0.5
C2b 214-223 10 0.5 0.1
C2b 207-223 10 0.5 0.015
C2b 119-223 1 .0 0.005 0.0011696
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of that found in a normal guinea pig (5) . Similarly, when HANE plasma was en-
riched with C2, enhanced kinin generation occurred (33) . Therefore, there is ade-
quate intact C2 to generate the active C2b peptide in vivo, and these data suggest
that it is possible to generate asimilar dose response to the above skin test by cleavage
of C2 in vivo. Consequently, the role ofC2 may be important in the pathogenesis
of angioedema .
We find that a second serine proteinase is required forthe release oftheC2 vasoactive
fragment as previously reported (33) . The aminoacid length ofthe active physiolog-
ical C2 fragment is not yet known, nor is it known what mightbe the in vivo enzyme
that releases the vasoactive peptide from its C2 precursor, Although plasmin is in-
hibited by Cl inhibitor, it is also complexed with a2-macroglobulin and a2-anti-
plasmin . Two aspects of plasmin metabolism still make it a candidate forthe in vivo
enzyme . The swelling episodes in angioedema areoften localized within asmall area
of the body, and are typically induced by minor trauma . The local boundaries of
the lesions may be a consequence of the preferential regulation of plasmin activity
in the extravascular spaces by C1 inhibitor. Alternatively, a tissue activation mecha-
nism, such as that ofa tissue plasminogen activation, might provide only local con-
centrations of active enzyme .
Summary
Synthetic peptides that correspond to the COOH-terminal portion of C2b en-
hance vascular permeability in human and guinea pig skin . In human studies, 1
nmol of the most active peptide of25-amino acid residues produced substantial local
edema . A pentapeptide and a heptapeptide corresponding to the COOH-terminal
sequence of C2b each induced contraction of estrous rat uterus in the micromole
range; a peptide of 25 amino acids from this region induced a like contraction of
rat uterus at a concentration 20-fold lower than the smaller peptides . The vascular
permeability of guinea pig skin was enhanced by doses of these synthetic peptides
in a similar fashion as that observed for the concentration of rat uterus .
The induction of localized edema by intradermal injection in both the guinea pig
and the human proceeds in the presence of antihistaminic drugs, suggesting that
there is a histamine-independent component to the observed increase in vascular
permeability .
Cleavage ofC2 with the enzymic subcomponent of Cl, Cls, yields only C2a and
C2b, and no small peptides, whereas cleavage ofC2 with Cls and plasmin yields
a set ofsmallpeptides . These plasmin-cleavedpeptides arederived from theCOOH
terminus of C2b, and they induce the contraction of estrous rat uterus .
We thank Dr. D. R. Bentley for providing us with C2 sequence before publication, and Dr.
Janice Young for synthesizingpeptides ofC2b . We also thankDr. Robert Sundel for assistance
with theguinea pig injections . For excellent technical assistance we thankAndreDauphinais,
Allan Gifford, Eric Karchmer, and Michael Regan .
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